Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA or MBC

 Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA or MBC

Pfizer’s Talzenna (talazoparib) Receives FDA Approval for BRCA-Mutated, HER2-Negative LA or MBC

Shots:

  • The approval is based on EMBRACA trial results assessing Talzenna (1mg) vs CT in 431 patients with BRCA-mutated HER2-negative locally advanced or metastatic breast cancer for a duration of 11.2 mos.
  • EMBRACA study results: mPFS (8.6 mos. vs 5.6mos.); ORR (62.6% vs 27.7%); reduction in risk of death 46%
  • Talzenna (talazoparib) is an PARP (poly ADP ribose polymerase) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline (inherited) BRCA-mutated HER2-negative LA or mBC in adults

Click here to read full press release/ article | Ref: Pfizer | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post